These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11583939)

  • 1. Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S11-5. PubMed ID: 11583939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Egidi MF; Gaber AO
    Transplantation; 2003 Feb; 75(4):572; author reply 573. PubMed ID: 12605133
    [No Abstract]   [Full Text] [Related]  

  • 3. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.
    Boardman RE; Alloway RR; Alexander JW; Buell JF; Cardi M; First MR; Hanaway MT; Munda R; Rogers CC; Roy-Chaudhury P; Susskind B; Trofe J; Woodle ES
    Transplant Proc; 2005 Mar; 37(2):814-6. PubMed ID: 15848541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus improves the two-year outcome of renal allografts in African-American patients.
    Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan BD
    Transpl Int; 2001 Jun; 14(3):135-42. PubMed ID: 11499902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
    Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
    Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
    Podder H; Kahan BD
    Transplant Proc; 2005 Nov; 37(9):3723-6. PubMed ID: 16386518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.
    Hricik DE; Knauss TC; Bodziak KA; Weigel K; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2003 Sep; 76(6):938-42. PubMed ID: 14508357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
    Youseff N; Small S
    Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus.
    Hricik DE; Augustine JJ; Knauss TC; Bodziak KA; Aeder M; Siegel C; Schulak JA
    Transplantation; 2007 Feb; 83(3):277-81. PubMed ID: 17297401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients.
    Shapiro R; Scantlebury VP; Jordan ML; Vivas CA; Jain A; Hakala TR; McCauley J; Johnston J; Randhawa P; Fedorek S; Gray E; Chesky A; Dvorchik I; Donaldson J; Fung JJ; Starzl TE
    Transplant Proc; 2002 Aug; 34(5):1651-2. PubMed ID: 12176521
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
    Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
    [No Abstract]   [Full Text] [Related]  

  • 15. Corticosteroid reduction with tacrolimus (CORRETA) TRIAL: a prospective Brazilian multicenter, randomized trial of early corticosteroid reduction versus regular corticosteroid dosage maintenance on a tacrolimus (Prograf) and mycophenolate mofetil (Cellcept) immunosuppression regimen in kidney transplant recipients: interim analysis.
    Garcia VD; Carvalho DB; Goncalves RT; Cavalcanti RL; Campos HH; Abbud-Filho M; Lobao-Neto AA
    Transplant Proc; 2008 Apr; 40(3):689-92. PubMed ID: 18454988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance immunosuppression: new agents and persistent dilemmas.
    Gonin JM
    Adv Ren Replace Ther; 2000 Apr; 7(2):95-116. PubMed ID: 10782729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.